Cargando…
Post-operative ctDNA monitoring in stage I colon cancer: A case report
Circulating tumor DNA (ctDNA) level monitoring after surgery for colon cancer has been studied in stage II and III colon cancer to risk-stratify patients for adjuvant therapy. However, there is less data regarding the role of this diagnostic tool in the management of stage I disease, where current r...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795219/ https://www.ncbi.nlm.nih.gov/pubmed/36591529 http://dx.doi.org/10.3389/fonc.2022.1074786 |
_version_ | 1784860210378047488 |
---|---|
author | Alden, Stephanie L. Dhani, Harmeet Palsuledesai, Charuta C. Krinshpun, Shifra Jurdi, Adham Christenson, Eric Browner, Ilene Rosner, Samuel |
author_facet | Alden, Stephanie L. Dhani, Harmeet Palsuledesai, Charuta C. Krinshpun, Shifra Jurdi, Adham Christenson, Eric Browner, Ilene Rosner, Samuel |
author_sort | Alden, Stephanie L. |
collection | PubMed |
description | Circulating tumor DNA (ctDNA) level monitoring after surgery for colon cancer has been studied in stage II and III colon cancer to risk-stratify patients for adjuvant therapy. However, there is less data regarding the role of this diagnostic tool in the management of stage I disease, where current recommended surveillance is limited to screening colonoscopy at one year. In this report, we describe the case of a 57-year-old man with stage I colon cancer who underwent complete resection with adequate lymph node surgical sampling, normal preoperative CEA and no evidence of metastatic disease on initial imaging. The patient elected to undergo serial ctDNA monitoring after surgery. Rising ctDNA levels, five months after resection, prompted cross-sectional imaging which demonstrated metastatic disease to the liver. The patient subsequently received five cycles of leucovorin, 5-fluorouracil, oxaliplatin, and irinotecan with bevacizumab (FOLFOXIRI-Bev) and definitive microwave ablation to the liver metastases, with resulting undetectable ctDNA levels. The patient’s imaging and colonoscopy one-year post-operatively showed no evidence of disease, with ctDNA levels remaining undetectable. This report highlights the value of ctDNA monitoring in patients with early-stage colon cancer and suggests that further, large-scale studies may be warranted to determine its appropriate clinical use. |
format | Online Article Text |
id | pubmed-9795219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97952192022-12-29 Post-operative ctDNA monitoring in stage I colon cancer: A case report Alden, Stephanie L. Dhani, Harmeet Palsuledesai, Charuta C. Krinshpun, Shifra Jurdi, Adham Christenson, Eric Browner, Ilene Rosner, Samuel Front Oncol Oncology Circulating tumor DNA (ctDNA) level monitoring after surgery for colon cancer has been studied in stage II and III colon cancer to risk-stratify patients for adjuvant therapy. However, there is less data regarding the role of this diagnostic tool in the management of stage I disease, where current recommended surveillance is limited to screening colonoscopy at one year. In this report, we describe the case of a 57-year-old man with stage I colon cancer who underwent complete resection with adequate lymph node surgical sampling, normal preoperative CEA and no evidence of metastatic disease on initial imaging. The patient elected to undergo serial ctDNA monitoring after surgery. Rising ctDNA levels, five months after resection, prompted cross-sectional imaging which demonstrated metastatic disease to the liver. The patient subsequently received five cycles of leucovorin, 5-fluorouracil, oxaliplatin, and irinotecan with bevacizumab (FOLFOXIRI-Bev) and definitive microwave ablation to the liver metastases, with resulting undetectable ctDNA levels. The patient’s imaging and colonoscopy one-year post-operatively showed no evidence of disease, with ctDNA levels remaining undetectable. This report highlights the value of ctDNA monitoring in patients with early-stage colon cancer and suggests that further, large-scale studies may be warranted to determine its appropriate clinical use. Frontiers Media S.A. 2022-12-14 /pmc/articles/PMC9795219/ /pubmed/36591529 http://dx.doi.org/10.3389/fonc.2022.1074786 Text en Copyright © 2022 Alden, Dhani, Palsuledesai, Krinshpun, Jurdi, Christenson, Browner and Rosner https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Alden, Stephanie L. Dhani, Harmeet Palsuledesai, Charuta C. Krinshpun, Shifra Jurdi, Adham Christenson, Eric Browner, Ilene Rosner, Samuel Post-operative ctDNA monitoring in stage I colon cancer: A case report |
title | Post-operative ctDNA monitoring in stage I colon cancer: A case report |
title_full | Post-operative ctDNA monitoring in stage I colon cancer: A case report |
title_fullStr | Post-operative ctDNA monitoring in stage I colon cancer: A case report |
title_full_unstemmed | Post-operative ctDNA monitoring in stage I colon cancer: A case report |
title_short | Post-operative ctDNA monitoring in stage I colon cancer: A case report |
title_sort | post-operative ctdna monitoring in stage i colon cancer: a case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795219/ https://www.ncbi.nlm.nih.gov/pubmed/36591529 http://dx.doi.org/10.3389/fonc.2022.1074786 |
work_keys_str_mv | AT aldenstephaniel postoperativectdnamonitoringinstageicoloncanceracasereport AT dhaniharmeet postoperativectdnamonitoringinstageicoloncanceracasereport AT palsuledesaicharutac postoperativectdnamonitoringinstageicoloncanceracasereport AT krinshpunshifra postoperativectdnamonitoringinstageicoloncanceracasereport AT jurdiadham postoperativectdnamonitoringinstageicoloncanceracasereport AT christensoneric postoperativectdnamonitoringinstageicoloncanceracasereport AT brownerilene postoperativectdnamonitoringinstageicoloncanceracasereport AT rosnersamuel postoperativectdnamonitoringinstageicoloncanceracasereport |